Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | PHASE2 | NOT YET_RECRUITING | 26 | — | — | May 4, 2026 | May 24, 2030 | Mar 18, 2026 | 3 | United States |
Evaluate clinical efficacy of pacritinib and selinexor in myelofibrosis patients who are JAK inhibitor-naïve and have anemia and thrombocytopenia by assessing spleen volume reduction (SVR) of 35% or greater compared to baseline as measured by imaging (MRI/CT)
| Arm | Type | Description |
|---|---|---|
| Pacritinib/Selinexor | EXPERIMENTAL | Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen. |
| Name | Type | Description |
|---|---|---|
| Pacritinib | DRUG | Pacritinib 200mg twice a day (BID) by mouth (PO) |
| Selinexor | DRUG | Selinexor 60mg once weekly (QW) by mouth (PO) |
Inclusion Criteria: * Adults ≥ 18 years of age capable of providing informed consent * Pathologically confirmed diagnosis of PMF, post-ET MF, or post-PV MF as per the World Health Organization (WHO) diagnostic criteria - Intermediate-1, Intermediate-2, or High-Risk disease by the Dynamic Internatio...